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Nine clinical benign prostatic hyperplasia (BPH) patients were treated with oral terazoin 
monotherapy (2 mg daily) for 12 weeks. Serum lipid levels (total cholesterolラtriglycerideラhighdensity 
lipoproteinラ lowdensity lipoproteinう apoproteins)were estimated prior to and every 4 weeks during 
treatment in 5 patients. International Prostate Symptom Score (IPSS) and pressure-flow study were 
evaluated before and 12 weeks after treatment in 4 patients. The total cholesterollevel decreased from 
a baseline of 21 0土36.6mg/dl by 6.6% at the 12th week. This result was not significant but suggested 
a favorable effect of terazosin on diminishing the risk of coronary heart disease. This efTect was 
marked especially in patients with a total cholesterollevel over 200 mg/dl. On the other handうIPSS
improved in al cases. The mean change ranged from 19.5 to 10.0 and the mean peak丘owrate from 
9.0 to 15.7 ml/s. On Sh訂ferヲsnomogramラ 1patient showed improvement of obstruction and the other 
3 patients were diagnosed as having weak detrusor without obstruction. Clinical BPH patients with 
hyperlipidemia may markedly benefit from terazosinラwhichis a safe and useful initial treatment for 
BPH. 



















(Acta U ro1. Jpn. 45: 827-830ラ 1999)
(A-I， II， B， C-I， II， E)を調べ，その変動を検討
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Table i.Changes of serum 5li) pid and apoprotein ievei(Mean土S.E.)during terazosin 
monotherapy (N = 
項目 基準値 (mg/dl) 治療前 4週後 8週後 12週後
T-Cho 150 -219 210 土36.6 203.2土20.0 190.8土16.3 191.4:1:10.6 
TG 50 -149 93.6土29.05 84.4土41.6 83.8:1:52.6 78.4土31.8
HDL 41 -80 60.0土18.3 56.0土11.6 54.8土14.4 54.6土13.3**
LDL 数式2により算出 132.9土50.7 130.3土22.8 119.2土15.4 121.1土17.8
アポ Al 95 -170 129.0ごと22.9 119.8土16.4 113.8:1: 18. 7* 117.8土16.9*
アポ A2 20 45 31.6土 2.3 29.4土 3.6 28.0土 3.5* 28.6土 3.2*
アポB 45 -125 97.4:1: 14.0 94.8土20.4 88.4土15.0 90.0土12.2
アポ C-2 0.7- 5.0 3.2土1.0 3.3土 0.4 2.8土 0.5 3.2土 0.6
アポ C-3 2.0-14.0 7.6土 3.0 6.9土 2.4 5.9土 2.1 6.8土 2.7
アポE 1.8- 6.5 4.9こと 1.4 4.4:1: 0.8 3.9:1: 0.7 4.0土 0.7
1. MEAN:1:SEで表示.2. LDL=TC-HDL-TG/5 (* P<0.05， ** P<O.OI). 
均値は Fig.1に示すごとく投与前 210.0土36.6→ 4





は正常化した.また， HDL，アポ A-I，A同I は正常
範閣内で有意な低下を示したが，その他の脂質，アポ
蛋白は有意な変動を認めなかった.
また， IPSS およぴ P戸ress叩ur陀晴℃珍~e-か幽-fl
ノパfラメ一夕一の結果を Table2に示すと共に Fig.3 




に IPSSの改善(平均19.5→ 10.0)，3例 (75.0%)
に Qmaxの改善(平均9.0→ 15.7) が見られた.
Abrams-Griffithの nomogram(Fig. 1)上，症例 1
(obstructed→unobstructed) および症例 2 (equi幽
vocal→unobstructed)の2例 (50%)で閉塞の改善，
症例 3，4 (equivocal → equivocal)の 2例 (50%)
で変化なしであったが，悪化症例は認めなかった.












治療前 4週後 8遜後 12過後
Fig. 1. Changes of total cholesterol level 
(Mean土S.E.) during terazosin treat-
ment (N=5). 
治療前 4週後 8週後 12週後
症例 l 274 195 166 200 
症例2 196 190 184 185 
症例3 199 208 195 200 
症例4 181 236 206 196 
症例5 200 187 203 176 










治療前 4週後 8週後 12週後
Fig. 2. Changes of total cholesterol level in a 
case of hyperlipidemia. 
(閉塞度 V→1)を認めたが，症例 2，3， 4の3
例は WeakDetrusor症例であり，閉塞の改善は症例















Table 2. IPSS and results of pressure-flow study before and after terazosin monotherapy 




















16 141 50 6 Obstructed V /Strong 
20 38 19 73 U nobstructed I/Normal 
4 35 30 262 Equivocal n/Weak 
16 27 20 210 U nobstructed O/Normal 
9 19 20 10 Equivocal O/Weak 
6 40 17 10 Equivocal n/Weak 
7 26 14 2 Equivocal I/Weak 
1 29 24 7 Equivocal I/Normal 
Pdet Qmax;最大尿流率時排尿筋庄 (cmH20)，Pmuo;排尿開始時排尿筋圧 (cmH20)， 
. 
Unobstructed 
O 10 15 20 25 
Qmax (ml/s) 
Fig. 3. Qtnax and Pdet Qmax are plotted on 
Abrams-Griffith's nomogram. The 
arrows show the changes in each case 
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Pdet (cmH20) 
Fig. 4. Qmax and PdetQmax are plotted on 
Shafer's nomogram. Arrows show the 
changes of linPURR in each case. 
れる4) 高血圧，高脂血症はいずれも動脈硬化性疾
なかでも冠動脈疾患の独立した危険因子であるこ


































は 4例全例に IPSS，4例中 317tlに最大尿流率の改
善を認めた. しかし，治療前の pressure-flowstudy 
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